-
CNQX: AMPA/Kainate Blockade in Neuroscience
2026-09-25
CNQX, also known as 6-cyano-7-nitroquinoxaline-2,3-dione, is a competitive AMPA and kainate receptor antagonist used to dissect glutamatergic neurotransmission. A 2024 rat study found that CNQX pretreatment in the paraventricular nucleus did not attenuate the measured cardiovascular responses to chemerin-9 delivered in the caudal nucleus tractus solitarius, unlike NMDA-receptor blockade.
-
BV6 and Cell-Death Assay Interpretation
2026-09-24
BV6 is an IAP antagonist used to investigate apoptosis and treatment sensitization in cancer models. This article connects its reported activity with a key cell-death research finding to show why orthogonal assays and pathway-specific interpretation matter.
-
AAPH Workflows for Protein Oxidation and Stress Assays
2026-09-24
AAPH offers a water-compatible, sustained source of peroxyl-radical stress for protein, erythrocyte, and antioxidant studies. This guide turns a hazelnut-protein finding into practical assay choices, with pilot conditions and troubleshooting clearly distinguished from published results.
-
Carvacrol: Cell-Cycle and TRP Redox Research
2026-09-23
Carvacrol, also known as 5-isopropyl-2-methylphenol, is a research compound with product-documented cell-cycle and apoptosis-related effects. A 2026 study identifies carvacrol as a non-electrophilic TRPA1 agonist that helps distinguish ligand responses from singlet-oxygen-driven channel modification.
-
BV6 and Lysosomal Context in Cancer Cell Death
2026-09-23
BV6 is an IAP antagonist used to investigate apoptosis induction in cancer cells, radiosensitization, and immune-mediated cytotoxicity. This article adds a lysoptosis-informed framework for distinguishing apoptotic signaling from lysosomal membrane permeabilization in advanced cell-death assays.
-
Dabigatran Etexilate: Oral Direct Thrombin Inhibition
2026-09-22
The reference review explains why dabigatran etexilate represented a major shift from vitamin K antagonists and injectable anticoagulants: it provided oral, rapid, and relatively predictable direct thrombin inhibition without routine INR-based dose adjustment. Its practical value was tempered by bleeding risk, gastrointestinal adverse effects, and the need to account for renal function when selecting and adjusting treatment.
-
Prestained Protein Marker: Triple-Color Workflow
2026-09-22
This guide explains how to use the Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) as a visible size reference and qualitative transfer check in SDS-PAGE and Western blot workflows. It is appropriate for Phosbind SDS-PAGE and fluorescent membrane imaging, but it should not be treated as a quantitative protein calibrant or a substitute for an unstained standard when dye-free detection is required.
-
Nurr1+ Neurons and Rat Claustrum Development
2026-09-21
Fang, Wang, and Naumann mapped the developmental appearance and embryonic birth timing of Nurr1-positive neurons across the rat claustrum, endopiriform region, and lateral cortex. By combining EdU birth dating with Nurr1 in situ hybridization, the study resolves subregional neurogenetic gradients and provides a framework for interpreting claustral organization during development.
-
Intravitreal Metformin in CNV and Retinal Degeneration
2026-09-21
This preclinical study shows that intravitreal metformin can suppress choroidal neovascularization, reduce inflammatory-cell infiltration, and limit light-induced retinal thinning in mouse models. Its main contribution is the parallel evaluation of anti-angiogenic and neuroprotective effects, while also identifying inflammation- and angiogenesis-associated gene responses that warrant further translational study.
-
Deep Learning for iPSC-CM Cardiotoxicity Screening
2026-09-20
Grafton et al. developed a high-content imaging and deep-learning workflow that assigns a single cardiotoxicity score to compounds tested in human iPSC-derived cardiomyocytes. The study shows how phenotype-first analysis can identify diverse liability classes early in drug discovery and guide follow-up testing before late-stage development.
-
VX-661: F508del CFTR Corrector Guide
2026-09-19
VX-661 is a F508del CFTR corrector that improves folding, trafficking, and cell-surface expression of defective CFTR in experimental systems. Its activity is context-dependent: variant identity, calnexin-dependent proteostasis, exposure conditions, and combination with VX-770 can change the measured rescue.
-
HyperScript™ Reverse Transcriptase for qPCR
2026-09-18
Learn how HyperScript™ Reverse Transcriptase (SKU K1071) can support RNA-to-cDNA conversion when cell viability, proliferation, or cytotoxicity studies generate limited or structurally complex RNA. This scenario-based guide separates product-supported capabilities from workflow recommendations for more defensible qPCR interpretation.
-
2'-O-Methyladenosine: Assay Workflow Guide
2026-09-18
Build more reliable nucleoside transport, RNA modification, and purine metabolomics experiments with 2'-O-Methyladenosine. This guide translates a high-sensitivity UHPLC–MS/MS workflow into practical preparation, extraction, assay, and troubleshooting decisions.
-
Nigericin as a Causal Probe of Ion–Metabolism Coupling
2026-09-17
Nigericin is a potassium/hydrogen ion carrier that converts membrane-gradient disruption into a measurable biological perturbation. This article connects intracellular pH modulation and mitochondrial ion transport with metabolism-aware assay design, while clarifying what recent antibiotic-resistance research does—and does not—demonstrate.
-
Nullscript: Reliable HDAC Assay Design
2026-09-17
This scenario-driven guide explains how Nullscript (SKU C3606) can support reproducible HDAC, viability, proliferation, and cytotoxicity workflows. It covers assay compatibility, stock preparation, interpretation of transcriptional inactivity, cardiac ischemia/reperfusion relevance, and practical product-selection criteria.